Bo Yu

Dr. Bo Yu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZYZhou Yang
Zhou Yang
TWTingfeng Wang
Tingfeng Wang
DWDejun Wu
Dejun Wu
ZMZhijun Min
Zhijun Min
JTJingyun Tan
Jingyun Tan
BYBo Yu
Bo Yu
Background: N6-Methyladenosine (m6A) modification has been implicated in multiple processes for colon cancer development. IGF2BP3 was a newly reported m6A reader, whereas its role in colon cancer remains unclear. Methods: The expression of m6A associated enzymes and total m6A level were measured by Western Blotting analysis and m6A RNA Methylation Quantification Kit respectively. Cell cycle was analyzed by flowcytometry. The interaction of IGF2BP3 and related targets was analyzed by RNA immunoprecipitation (RIP) and m6A RNA immunoprecipitation (MeRIP) assays. Results: We investigated all m6A regulated enzymes in colon cancer and found only the overexpression of IGF2BP3 was associated with cancer progression and survival based on The Cancer Genome Atlas (TCGA) databases. Additionally, we also demonstrated IGF2BP3 was associated with DNA replication in the cell cycle. Knockdown of IGF2BP3 significantly repressed percentage of S phase of cell cycle as well as cell proliferation. Further research demonstrated IGF2BP3 bound to the mRNA of Cyclin D1 (CCND1, checkpoint of G1/S phase of cell cycle) and reduced its mRNA stability via reading m6A modification in the CDS region. Overexpression of Cyclin D1 in IGF2BP3 down-regulated cells completely rescued the inhibited percentage of S phase in cell cycle as well as cell proliferation. Additionally, we also demonstrated a similar role of IGF2BP3 at VEGF. IGF2BP3 bound to the mRNA of VEGF and reads m6A modification, thus regulated both expression and stability of VEGF mRNA. Knockdown of IGF2BP3 repressed angiogenesis in colon cancer via regulating VEGF. Conclusion: Knockdown of IGF2BP3 repressed DNA replication in the S phase of cell cycle and angiogenesis via reading m6A modification of CCND1 and VEGF respectively. IGF2BP3 was a possible prognosis marker and potential therapeutic target of colon cancer.

6 January 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ZYZhou Yang
Zhou Yang
XWXiyi Wei
Xiyi Wei
YPYitong Pan
Yitong Pan
JXJingyuan Xu
Jingyuan Xu
YSYan Si
Yan Si
BYBo Yu
Bo Yu
Increasing evidence has indicated a close association between immune infiltration in cancer and clinical outcomes. However, related research in thyroid cancer is still deficient. Our research comprehensively investigated the immune infiltration of thyroid cancer. Data derived from TCGA and GEO databases were analyzed by the CIBERSORT, ESTIMATE, and EPIC algorithms. The CIBERSORT algorithm calculates the proportions of 22 types of immune cells. ESTIMATE algorithm calculates a stromal score to represent all stromal cells in cancer. The EPIC algorithm calculates the proportions of cancer-associated fibroblasts (CAFs) and endothelial cells (ECs), which are the main components of stromal cells. We analyzed the correlation of immune infiltration with clinical characteristics and outcomes of patients. We determined that the infiltration of CD8+ T cells improved the survival of thyroid cancer patients. Overexpression of immune checkpoints was closely related to the development of thyroid cancer. In general, stromal cells were associated with the progression of thyroid cancer. Interestingly, CAFs and ECs had opposite roles in this process. In addition, the BRAFV600E mutation was related to the upregulation of immune checkpoints and CAFs and the downregulation of CD8+ T cells and ECs. Finally, we constructed an immune risk score model to predict the prognosis and development of thyroid cancer. Our research demonstrated a comprehensive panorama of immune infiltration in thyroid cancer, which may provide potential value for immunotherapy.

18 May 2020 in International Reviews of Immunology
Verified
Journal Article
Closed access
ZYZhou Yang
Zhou Yang
ZMZhijun Min
Zhijun Min
BYBo Yu
Bo Yu
Reactive oxygen species (ROS) is a kind of single electron reduction product of oxygen in vivo. Because they contain unpaired electrons, ROS has high chemical reactivity. Various researches of ROS are focused on DNA damage, cell apoptosis, oxidative stress. Actually, ROS is also closed related to immune regulation. Based on this, we review the research in immune regulated ROS production, regulation of ROS on inflammatory factors and inflammatory response, antigen presentation and macrophage polarization for better understanding of its role.

12 January 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ZYZhou Yang
Zhou Yang
YHYijun Huang
Yijun Huang
LZLei Zhu
Lei Zhu
KYKai Yang
Kai Yang
KLKun Liang
Kun Liang
BYBo Yu
Bo Yu
As a member of Sirtuins family, SIRT6 participates in the physiological and pathological progress of DNA repair, anti-aging, metabolism, and so on. Several studies have demonstrated that knockdown of SIRT6 inhibited the development of atherosclerosis (AS), indicated SIRT6 as a protective factor for AS. However, we confirmed SIRT6 was significantly overexpressed in human unstable carotid plaques compared with stable carotid plaques. This result indicated a more complex role of SIRT6 in AS. Furthermore, we constructed mice model with unstable carotid plaque and injected them with SIRT6 overexpressed adeno-associated virus (AAV-SIRT6). AAV-SIRT6 significantly promoted angiogenesis as well as hemorrhage in plaques. In vitro, we demonstrated overexpression of SIRT6 prevented HIF-1α from degradation by deubiquitination at K37 and K532 of HIF-1α, thus promoted the expression of HIF-1α under both normoxia and hypoxia in human umbilical vein endothelial cells (HUVECs). Through regulating HIF-1α, overexpression of SIRT6 promoted invasion, migration, proliferation, as well as tube formation ability of HUVECs. Interestingly, under different conditions, SIRT6 played different roles in the function of HUVECs. Under oxidative stress, another important pathological environment for AS, SIRT6 bound to the promoter of Catalase, a main reactive oxygen species scavenger, and depleted H3K56 acetylation, thus inhibited expression and activity of Catalase at the transcriptional level. Subsequently, inhibited Catalase promoted reactive oxygen species (ROS) under oxidative stress. Accumulated ROS further aggravated oxidative stress injury of HUVECs. On one hand, SIRT6 promoted angiogenesis in plaque via HIF-1α under hypoxia. On the other hand, SIRT6 promoted injury of neovascular via ROS under oxidative stress. It is this process of continuous growth and damage that leads to hemorrhage in carotid plaque. In conclusion, we innovatively confirmed SIRT6 promoted the angiogenesis and IPH via promoting HIF-1α and ROS in different environments, thus disclosed the unknowing danger of SIRT6.

27 February 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZYZhou Yang
Zhou Yang
YQYingjun Quan
Yingjun Quan
YCYusheng Chen
Yusheng Chen
YHYijun Huang
Yijun Huang
RHRenhong Huang
Renhong Huang
BYBo Yu
Bo Yu

1 November 2020 in Cardiovascular Pathology
Verified
Journal Article
Closed access
YHYijun Huang
Yijun Huang
LZLei Zhu
Lei Zhu
JTJinyun Tan
Jinyun Tan
WGWencheng Guo
Wencheng Guo
ZYZhou Yang
Zhou Yang
BYBo Yu
Bo Yu